Hypertension and nephrology

[Current diagnosis and treatment of membranous nephropathy]

STUDINGER Péter, CSEPREKÁL Orsolya, FINTHA Attila, KARDOS Magdolna, TISLÉR András

DECEMBER 10, 2013

Hypertension and nephrology - 2013;17(05-06)

[Primary membranous nephropathy is a common glomerular disorder characterized by subepithelial immune deposits. The pathomechanism underlying these lesions has only recently been elucidated: M-type phospholipase A2receptor (PLA2R) protein emerged as being the leading autoantigen. Antibodies to PLA2R, typically of IgG4 subclass are expressed in 70-80% of patients with primary membranous nephropathy. The level of autoantibody to PLA2R was shown to correlate with disease severity and to change parallel with disease activity in response to therapy. While mild forms of the disease are prone to spontaneous remission and carry excellent prognosis, severe forms often progress into end-stage renal disease without treatment and necessitate immunosuppression. The latest guidelines recommend the application of corticosteroids with alkylating agents or calcineurin inhibitors as first-line therapy. Promising new therapies that are currently being explored for this disease include rituximab, mycophenolate mofetil, and adrenocorticotropic hormone.]

COMMENTS

0 comments

Further articles in this publication

Hypertension and nephrology

[Monitoring of effectiveness of ramipril-amlodipine fixed combination, a non-interventional trial (Ramona study). Subgroup analysis of patients with chronic kidney disease]

SIMONYI Gábor

[Hypertension and chronic kidney disease are independent cardiovascular risk factors. The 5th Cardiovascular Consensus Conference has recommended chronic kidney disease in high-risk category. In chronic kidney disease hypertension is observed in most cases. In patients with chronic kidney disease blood pressure targets are as 140/90 mmHg blood pressure below must be achieved without overt proteinuria. In chronic kidney disease combined antihypertensive therapy treatment should be initiated according the Hungarian Society of Hypertension recommendations. Aims: Monitoring the effectiveness and safety of the fix combination of ramipril/amlodipine Egiramlon® therapy in chronic kidney disease suffering from mild or moderate hypertension despite antihypertensive treatment. Patients and methods: Open, prospective, phase IV clinical observational study, which involved known chronic kidney disease (age over 18 years) with mild or moderate hypertension. Ramipril/amlodipine fixed combination (5/5, 5/10, 10/5 or, 10/10 mg) were administered or titrated in three visits, during the 4 months of trial period. The doses of the fixed combination drugs were determined individually during the visits by the 923 physicians involved in the study. The target blood pressure value was <140/90 mmHg according the new guidelines of ESH/ESC. Results: 70.1% of total patient (9169) was fulfilled the protocol during the four month of trial (6423 patients). In this population 194 patients suffered from chronic kidney disease. The age of patients was 68.52±1.84 (mean±SD) years, 85 (43.8) women and 109 (56.2%) men. 74.74% of total patients with chronic kidney disease has reached target blood pressure at the end of 4th month (primary endpoint). The blood pressure has decreased significantly (all p<0.0001) from 158.04/90.46±9.97/8.30 mmHg (1. visit) to 138.77/82.12±10.68/7.21 mmHg 2. visit and to 130.40/78.59±7.56/5.75 at the and of trial (3. visit), it means -27.64/- 11.87 mmHg decrease from the beginning of the 4th Month (3. visit). eGFR level increased significantly from 46.3±16.49 ml/min/1,73m2 to 49.0±19.58 ml/min/1,73m2. Patients suffered from chronic kidney disease have tolerated well the various doses of fixed combination of ramipril/amlodipine, and adverse events have no occurred correlation of treatment.]

Hypertension and nephrology

[Training With and Against Hypertension ]

APOR Péter

Hypertension and nephrology

[Non-Medicinal, Non-Lifestyle Treatments in Hypertension ]

LÉGRÁDY Péter, BAJCSI Dóra, FEJES Imola, ÁBRAHÁM György

Hypertension and nephrology

[Relationship of Adipokins with Diurnal Changes in Blood Pressure ]

KOVÁCS Imre, TARJÁN Jenő, HEGEDŰS Zoltán, VÉGH Tibor, HORVÁTH Judit, KERN András, KOVÁCS Nóra, KOLLER Ákos

Hypertension and nephrology

[Early histopathological changes in new onset diabetes mellitus after renal transplantation]

IBRAHIM Munir Yasmin, BORDA Bernadett, LENGYEL Csaba, VÁRKONYI Tamás, KEMÉNY Éva, SZABÓ Viktor, KUBIK András, LÁZÁR György

[Introduction: New-onset diabetes after transplantation (NODAT) is one of the most common complications following kidney transplantation. The diagnosis of NODAT is often late or missed, therefore it impairs the implanted renal allograft. Patients and methods: Patients were randomized to receive cyclosporine A- or tacrolimusbased immunosuppression. One year after the transplantation, fasting and oral glucose tolerance tests were performed, and the patients were assigned to one of the following three groups based on the results: normal, impaired fasting glucose/impaired glucose tolerance (IFG/IGT), NODAT. Age, laboratory results, renal function, morphological abnormalities, and changes in the Banff score were evaluated. Results: NODAT developed in 14% of patients receiving cyclosporine A-based immunosuppression and in 26% of patients taking tacrolimus (p=0.0002). Albumin levels were similar, but uric acid level (p=0.002) and the age of the recipient (p=0.003) were significantly different between the diabetic and the normal group. The evaluation of renal function showed no significant differences in case of serum creatinine level, eGFR, and urea level. Evaluation of tissue samples revealed that acute cellular rejection (ACR) and interstitial fibrosis/ tubular atrophy (IF/TA) were significantly different in the NODAT group. Changes in the Banff score provided significant difference regarding tubulitis (“t”) and interstitial inflammation (“i”) (p=0.05). Discussion: The pathological effect of new-onset diabetes after kidney transplantation can be detected in the morphology of the renal allograft earlier, before any signs of functional impairment.]

All articles in the issue

Related contents

Lege Artis Medicinae

[Insulin: alfa and omega]

KIS János Tibor, BALOGH Bernadett, KISS Zsófia, SCHANDL László

[Type 1 diabetes (T1DM) is caused by the autoimmune death of insulin-producing β-cells. In the background there is by all probability the primary antigen (if the theory of primary antigen is correct) the insulin itself or the proinsulin. However, treatment of T1DM is virtually equivalent to the insulin treatment. The earlier we recognize T1DM and start treatment, the better gly­caemic results we achieve, the more likely we can maintain all functional β-cell stocks. Insulin also plays a key role in the immunopathogenesis, development and treatment of T1DM, thus insulin is the alpha and omega in this condition.]

Hypertension and nephrology

[Lupus nephritis, 2022]

CZIROK Szabina, DOLGOS Szilveszter

[The lupus nephritis (LN) is one of the most frequent manifestation of SLE which causes higher morbiditiy and mortalitiy of the patients if it appears. Although the use of glucocorticoides, cyclophosphamide and mycofenolat mofetil and the protection of the kidney with conservative therapy has significantly improved the outcome of the disease, but the long-term renal outcome and risk of death from LN have not changes over the last 20 years. Furthermore, the side effect of our medications used as part of the standard immunomodulatory therapy are not negligible. The better understanding of the pathomechanism of different medical conditions (hypertension, diabetes mellitus etc.) has helped to combine medications with different therapeutic targets which result more effective and favorable side-effect profile therapy. Therefore, it is not suprising that, in parallel with improvement of the immunology, with better knowlege about the patomechanism of SLE can lead to the new combined, targeted treatments which have broadened the therapeutic options. In addition to the immunmodulatory therapy, a drug with new mechanism of action has become available to slow the progression of chronic kidney diseases. The purpose of this summary is to briefly summarize the current knowledge available and assist clinicians in the daily practice of patients with LN to give suggestion for more effective and personalized therapeutic options.]

Hypertension and nephrology

[The safety and efficacy of LCP-tacrolimus in maintenance immunosuppressive therapy after kidney transplantation]

CSEPREKÁL Orsolya, KEGLEVICH András, REMPORT Ádám

[This paper provides a comprehensive review of a new, innovative formulation of one of the cornerstones of immunosuppressive maintenance therapy, tacrolimus (LifeCycle Pharma Tac, LCP-Tac, LCPT). This brief overview provides a deeper insight into the scientific literature of LCP-Tac. In summary, once daily LCP-Tac, a medication available in routine clinical practice, can provide effective and safe blood levels in renal transplant patients. Furthermore LCP-Tac may require lower doses of tacrolimus due to increased bioavailability thanks to the innovative MeltDose® technology.]

Lege Artis Medicinae

[Efficiency and safety of the vaccination against H1N1 influenza virus in inflammatory bowel disease]

FARKAS Klaudia, JANKOVICS István, MELLES Márta, NAGY Ferenc, SZEPES Zoltán, WITTMANN Tibor, MOLNÁR Tamás

[INTRODUCTION - Inactivated influenza and H1N1 vaccination is recommended yearly for patients with inflammatory bowel disease receiving immunosuppressive therapy; however, immunomodulator and biological therapy might impair the immune response to the vaccination. In our study, we assessed whether immunity can develop in response to H1N1 influenza vaccination in patients receiving immunomodulator and/or biological therapy. We also assessed the occurrence of side effects after the immunisation in these patients. PATIENTS AND METHODS - In our prospective study, blood samples were obtained from 24 patients (12 Crohn’sdisease, 12 ulcerative colitis) one month after immunisation against influenza A/California/ 07/2009 (H1N1) virus. At the time of vaccination, all patients have been receiving immunomodulator and/or biological therapy for at least three month. Antiviral antibodies were detected by using microneutralisation assay. The safety of the vaccination was assessed by questionnaires. RESULTS - Every patient developed complete immunity against influenza A (H1N1) virus, independently from the type of immunosuppressive therapy. Regarding side effects, local symptoms occurred in six patients and systemic symptoms in another six patients. Mild diarrhea occurred in five patients. Moderate exacerbation of the disease was observed in 2 patients with Crohn’s disease and in one patient with ulcerative colitis. CONCLUSIONS - According to our results, immunocompromised patients with IBD can be safely advised to receive the vaccination. In our study, all patients developed adequate immunity according to microneutralisation titers.]

Lege Artis Medicinae

[Management of inhibitory haemophilia A and aquired haemophilia]

PFLIEGLER György, RÁK Kálmán, KRÁLL Géza, SAS Géza, HAYNAL Imre

[The authors survey the occurrence and the laboratory and clinical differences of factor VIU antibodies in haemophiliacs (allo) and in non-haemophiliacs (auto) as well as their titer and measurement. The recent therapeutic modalities used in prevention, management of acute bleeds and suppression of antibody development or in duction of immune tolerance are detailed. ]